Halozyme Therapeutics (HALO) Short-term Investments (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Short-term Investments data on file, last reported at $8.9 million in Q1 2026.

• On a quarterly basis, Short-term Investments fell 98.45% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $8.9 million, a 98.45% decrease from a year earlier, with the FY2025 full-year figure at $9.0 million, down 98.13% from the prior year.
• Short-term Investments for Q1 2026 stood at $8.9 million, down from $9.0 million in the prior quarter.
• Over the last five years, Short-term Investments for HALO reached as high as $668.3 million in Q1 2022 and fell as low as $8.9 million in Q1 2026.
• Historically, Short-term Investments has averaged $279.8 million across 5 years, with a median of $217.6 million in 2023.
• Across the five-year window, Short-term Investments surged 168.4% in 2024 and sank 98.45% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $128.6 million in 2022, then soared by 69.23% to $217.6 million in 2023, then surged by 120.66% to $480.2 million in 2024, then plunged by 98.13% to $9.0 million in 2025, then declined by 1.41% to $8.9 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $8.9 million in Q1 2026, $9.0 million in Q4 2025, and $282.3 million in Q3 2025.